K. Lyons

发表

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment.

Karen Holmes, Kathy Lyons, Joseph Kessler, 2004, Bioorganic & medicinal chemistry letters.

Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.

J. Wityak, A. Beresford, L. Mrzljak, 2015, Journal of medicinal chemistry.

CCR 5 Blockade Modulates Inflammation and Alloimmunity in Primates 1

Miller, R. Pierson, J. Šál, 2007 .

CCR5 Blockade Modulates Inflammation and Alloimmunity in Primates1

R. Pierson, J. Mudgett, J. Demartino, 2007, The Journal of Immunology.

Bicyclo[2.2.2]octyltriazole inhibitors of 11β-hydoxysteroid dehydrogenase type 1. Pharmacological agents for the treatment of metabolic syndrome.

R. Thieringer, J. Balkovec, S. T. Waddell, 2011, Bioorganic & medicinal chemistry letters.

(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

G. Scapin, Suresh B. Singh, N. Thornberry, 2007, Bioorganic & medicinal chemistry letters.

Optimization of 1,4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.

N. Thornberry, B. Leiting, G. Eiermann, 2007, Bioorganic & medicinal chemistry letters.

Inhibition of Dipeptidyl-Peptidase IV Does Not Increase Circulating IGF-1 Concentrations in Growing Pigs

B. Leiting, G. Hickey, K. Pryor, 2006, Experimental biology and medicine.

Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].

Ping Chen, G. Scapin, R. S. Roy, 2013, Bioorganic & medicinal chemistry letters.

Substituted biaryl pyrazoles as sodium channel blockers.

V. Warren, Sanjeev Kumar, M. Fisher, 2010, Bioorganic & medicinal chemistry letters.

Substituted phenyl triazoles as selective inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1.

J. Balkovec, S. T. Waddell, M. Maletic, 2011, Bioorganic & medicinal chemistry letters.

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.

D. Hazuda, W. Schleif, E. Emini, 2004, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.

R. Bürli, M. Lamers, G. Mcallister, 2013, Journal of medicinal chemistry.

Assessment of chloroquine treatment for modulating autophagy flux in brain of WT and HD mice.

D. Marchionini, C. Dominguez, H. Birch, 2014, Journal of Huntington's disease.

Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.

Kathy Lyons, Ping Chen, Dennis Feng, 2014, Journal of medicinal chemistry.

Discovery of MK-7725, A Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity.

M. Reitman, J. Metzger, O. Palyha, 2011, ACS medicinal chemistry letters.

Integrating qualitative and quantitative liquid chromatography/tandem mass spectrometric analysis to support drug discovery.

C E Hop, Q Chen, G Kwei, 1999, Rapid communications in mass spectrometry : RCM.

The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerization.

V. Hornak, W. Schafer, C. Welch, 2012, Bioorganic & Medicinal Chemistry.

Antiobesity Effect of MK-5046, a Novel Bombesin Receptor Subtype-3 Agonist

M. Reitman, J. Metzger, Liming Yang, 2011, Journal of Pharmacology and Experimental Therapeutics.

Discovery of benzodiazepine sulfonamide-based bombesin receptor subtype 3 agonists and their unusual chirality.

V. Hornak, W. Schafer, C. Welch, 2011, ACS medicinal chemistry letters.

Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors.

David D. Manning, J. Wityak, D. Kitchen, 2015, Journal of medicinal chemistry.

Use of a Small Molecule CCR5 Inhibitor in Macaques to Treat Simian Immunodeficiency Virus Infection or Prevent Simian–Human Immunodeficiency Virus Infection

R. Doms, John P. Moore, Steven Wolinsky, 2003, The Journal of experimental medicine.

Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.

G. Scapin, Suresh B. Singh, N. Thornberry, 2007, Bioorganic & medicinal chemistry letters.

Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.

V. Warren, Sanjeev Kumar, M. Fisher, 2010, Bioorganic & medicinal chemistry letters.